Clinical Trial Update: Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating hetrombopag for secondary prevention of thrombocytopenia induced by XPO-1 inhibitors in lymphoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia
• Lymphoma

Drugs mentioned

• Hetrombopag (hetrombopag)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Chemotherapy-Induced Thrombocytopenia | Phase 2 | Status: UNKNOWN